2017 Fiscal Year Final Research Report
Taking advantage of a pitfall in glioma cancer stem cell epigenetics to develop novel therapies directed to cancer stem cells
| Project/Area Number |
16K15640
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Yamagata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OKADA MASASHI 山形大学, 医学部, 講師 (70512614)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | glioma-initiating cells |
|---|
| Outline of Final Research Achievements |
Cancer stem cells are a small subpopulation of immature, undifferentiated tumor cells characterized by therapy resistance as well as by their ability to initiate tumors on one hand and on the other to undergo differentiation into mature, non-cancer stem cells that no longer retain therapy resistance or tumor-initiating capacity. As such, cancer stem cells are deemed a major culprit of post-treatment tumor recurrence and therefore a key therapeutic target in the development of curative cancer therapies. Here in this research project, we tested our original working hypothesis that tri-methylation at H3K27 promotes the differentiation of glioma stem cells, an idea apparently paradoxical to what has been widely believed in the field of glioma stem cell research, in an attempt to develop novel therapies directed against glioma stem cells.
|
| Free Research Field |
脳神経外科学、脳腫瘍学
|
